Thermo Fisher Scientific Expands Clinical Trial Services Capabilities with new Facility in India
News Oct 25, 2007
Thermo Fisher Scientific Inc. has announced that it has broken ground on a new $17 million (USD) facility in Ahmadabad, India, to support growing demand for biopharma services in that country.
The facility will focus on packaging, global distribution and logistics management of tightly regulated pharmaceutical samples to patients participating in clinical trials across the globe. It will complement existing clinical services operations in the U.S., Europe and Asia. The company expects to open the new 100,000-square-foot facility by spring of 2008, and add approximately 100 employees in the first year of operation.
"Large pharmaceutical companies are focusing more and more on India for their future clinical research and development programs," said Marijn E. Dekkers, president and chief executive officer of Thermo Fisher Scientific.
"They are looking to outsource their clinical trials management to partners who know how to work within changing regional and global clinical trial regulations. By expanding our capacity to serve the needs of both multi- national and local pharmaceutical companies, we will be able to bring a higher level of technology, quality and expertise to facilitate clinical trials," said Dekkers.
Thermo Fisher Scientific has taken significant steps over the past few years to increase its overall presence in India, adding sales and manufacturing facilities to support growing markets, including biopharma services and biospecimen storage, life sciences research and industrial processing.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE